Skip to content

Kailera Therapeutics

US · KLRA #3073 by market cap Listed 2026
11.02 -0.56 -4.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.67 Expensive vs history 85th percentile
5-year average -2.82 · #200 of 513 in Biotechnology
P/E ratio -5.89 Expensive vs history 74th percentile
5-year average -507.07 · forward -3.44
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Kailera Therapeutics (KLRA) 1.43B -4.89 1.39 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value17.76 Economic moatNone UncertaintyVery High

Trading 61.2% below Morningstar's fair value estimate.

Fair value

Given the significant price pressure over the last year, Kailera Therapeutics Inc might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 25% discount to our quantitative fair value estimate of $17.76 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 1.9, which falls in the bottom 20% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

On a different note, the company's balance sheet is potentially concerning. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. The firm's long term debt to assets ratio of 0.01, a core component of leverage, lies in the bottom 30% compared with global peers. With little long-term debt relative to assets, this firm has a "lazy" balance sheet, which can depress returns on invested capital. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Kailera Therapeutics discussion 0 comments

Add a comment